Holen Sie sich die Stockscreener-App
22.53
5.73%
1.22
Handel nachbörslich:
22.50
-0.03
-0.13%
Schlusskurs vom Vortag:
$21.31
Offen:
$20.92
24-Stunden-Volumen:
216.52K
Relative Volume:
1.70
Marktkapitalisierung:
$369.22M
Einnahmen:
$153.73M
Nettoeinkommen (Verlust:
$-106.79M
KGV:
-12.66
EPS:
-1.78
Netto-Cashflow:
$-115.93M
1W Leistung:
+10.06%
1M Leistung:
+54.32%
6M Leistung:
+112.55%
1J Leistung:
+65.66%
1-Tages-Spanne:
$20.73
$22.76
1-Wochen-Bereich:
$18.65
$22.76
52-Wochen-Spanne:
$5.231
$22.76
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
22.53 | 349.22M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Sutro Biopharma (STRO) to Release Quarterly Earnings on Thursday - Defense World
Sutro Biopharma: Transformed leadership and advanced ADC pipeline drive clinical progress, with key data due mid-year - TradingView
Sutro Biopharma: Transformed leadership and advanced ADC platform drive rapid clinical progress and innovation - TradingView
Sutro Biopharma (STRO) GC reports new RSUs, options and tax share withholdings - Stock Titan
Sutro Biopharma (NASDAQ: STRO) CSO receives RSUs and options - Stock Titan
Sutro Biopharma (STRO) CFO awarded 40,000 options and 5,000 RSUs - Stock Titan
Sutro Biopharma (STRO) CEO receives RSU and option grants, shares withheld for taxes - Stock Titan
174,843 Shares in Sutro Biopharma, Inc. $STRO Purchased by GSA Capital Partners LLP - MarketBeat
Sutro Biopharma, Inc. (STRO) Presents at 16th Annual World ADC London SummitSlideshow - Seeking Alpha
STRO PE Ratio & Valuation, Is STRO Overvalued - Intellectia AI
STRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sutro Biopharma to participate in key investor conferences - Traders Union
Sutro Biopharma to Participate in Upcoming Investor Conferences - marketscreener.com
Sutro Biopharma Announces Participation at the 16th World ADC London Summit - The Manila Times
World ADC London panels spotlight Sutro Biopharma’s dual-payload ADCs - Stock Titan
Earnings Miss: Is Sutro Biopharma Inc a stock for growth or value investors2025 Key Highlights & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Is Sutro Biopharma Inc. a stock for growth or value investorsQuarterly Portfolio Report & Accurate Buy Signal Notifications - mfd.ru
Is Sutro Biopharma Inc. in a bullish channelTrend Reversal & Low Drawdown Trading Strategies - mfd.ru
Levels Update: Should I invest in Sutro Biopharma Inc before earningsEarnings Overview Report & High Yield Equity Trading Tips - baoquankhu1.vn
Is Sutro Biopharma Inc. (S09) stock a contrarian opportunity2025 Macro Impact & Real-Time Chart Breakout Alerts - mfd.ru
STRO Technical Analysis & Stock Price Forecast - Intellectia AI
Suvretta Capital exits Sutro Biopharma (STRO), reports 0% beneficial stake - Stock Titan
Sutro Biopharma prices $110M common stock offering - MSN
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? - Yahoo Finance
Jobs Data: Can Sutro Biopharma Inc deliver alpha2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
Sutro Biopharma prices $110 million common stock offering By Investing.com - Investing.com Nigeria
Performance Recap: Why is Sutro Biopharma Inc stock going downJuly 2025 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Sutro Biopharma Highlights ADC Platform in New Presentation - TipRanks
Sutro Biopharma Signs Underwriting Agreement With Leerink Partners and TD Securities (USA) - TradingView
Sutro Biopharma Stock Rises 8% After Announcement Of Pricing Of 7.9 Mln Shares - Nasdaq
Sutro Biopharma Prices $110 Mln Underwritten Offering; Stock Jumps 18% - RTTNews
Sutro Biopharma (STRO) Sees Joint Management in Upcoming Offerin - GuruFocus
Sutro Biopharma prices $110 million common stock offering - Investing.com
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) has caught the attention of institutional investors who hold a sizeable 41% stake - Yahoo Finance
Aug Sectors: Why is Sutro Biopharma Inc stock going downTrade Risk Summary & Stock Portfolio Risk Management - baoquankhu1.vn
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation - Sahm
Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Expands By 30.5% - MarketBeat
Pullback Watch: Is Sutro Biopharma Inc in a bullish channelWeekly Gains Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Macro Review: Should I invest in Sutro Biopharma Inc before earningsTrade Volume Summary & Weekly High Potential Alerts - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Options Flow: Is Sutro Biopharma Inc affected by consumer sentimentJuly 2025 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Sutro Biopharma (STRO) soars 5.9%: Is further upside left in the stock? - MSN
Winners Losers: Does MFS Government Markets Income Trust have a sustainable dividendEntry Point & Short-Term Trading Alerts - baoquankhu1.vn
Trade Recap: Is Adlai Nortye Ltd Depositary Receipt part of any ETF2025 Geopolitical Influence & Reliable Price Breakout Alerts - baoquankhu1.vn
Panic Selling: Is Sutro Biopharma Inc affected by consumer sentimentJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Sutro Biopharma (NASDAQ:STRO) Upgraded to “Market Outperform” at Citizens Jmp - Defense World
STRO Receives Upgraded Analyst Rating from Citizens | STRO Stock News - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Raised to "Market Outperform" at Citizens Jmp - MarketBeat
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sutro Biopharma Inc-Aktie (STRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):